Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

SRZN vs COCP: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–2 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 3 – 2 COCP (1 Tie) Matrix Metrics: SRZN 5 – 2 COCP

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $29.98 (N/M Forward P/E, -485.4% operating margin), whereas COCP carries 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin).

  • Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -3063.6% operating margin) and revenue trajectory (+408.6% vs. +26.9% YoY).
  • Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (33.2/100 SELL) and COCP (38.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs COCP
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$29.98
-7.24% 1D
Market Cap $602.5M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 67% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 50.0 Fund 34.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (10.9% over 20 days), RSI 53
RSI-14: 53.1 · SMA20: $29.76 · SMA50: $26.28
COCP NASDAQ
Cocrystal Pharma, Inc. Common Stock
Pharmaceutical Preparations
$1.01
+3.3% 1D
Market Cap $18.9M
TTM Revenue $330,000
Forward P/E N/M
Beta / 30D Vol 0.98β · 54% Vol
Unified Composite Score
38.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 51
RSI-14: 50.6 · SMA20: $1.00 · SMA50: $1.07

6-Pillar Scorecard Institutional Category Breakdown (SRZN 3 – 2 COCP)

Columns: Metric · SRZN · COCP
1. Valuation Multiples COCP
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 48.3x 47.3x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% +26.9%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $330,000
Market Cap $602.5M $18.9M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -485.4% -3063.6%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -62.8% -311.7%
4. Balance Sheet & Cash Flow COCP
Cash Generation (TTM) -$31M -$7.6M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash $3.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (5th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (5) vs COCP (2)
Institutional Metric SRZN COCP Criterion Row Edge
Market Capitalization
Scale
$602.5M $18.9M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+408.6% +26.9% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -3063.6% Higher Margin SRZN
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-62.8% -311.7% Higher ROE SRZN
52-Week Range Position
Momentum
69% ($12–$38) 20% ($1–$2) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 67% Vol 0.98β · 54% Vol Lower Realized Risk COCP
Unified Institutional Score
Composite Signal
33.2 / 100 (SELL) 38.7 / 100 (SELL) Higher Composite COCP
Trailing 12M Revenue (USD)
Operating Scale
$11M $330,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 48.3x EV/Rev N/M PEG · 47.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$7.6M ($3.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +19.06 pp
SRZN: +25.76% · COCP: +6.7%
3M Horizon SRZN +36.65 pp
SRZN: +24.86% · COCP: -11.79%
6M Horizon SRZN +29.42 pp
SRZN: +17.25% · COCP: -12.17%
1Y Horizon SRZN +132.91 pp
SRZN: +130.97% · COCP: -1.94%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue COCP Revenue SRZN Op. Margin COCP Op. Margin Margin Leader
FY2011 N/A $10M N/A -30.6% COCP
FY2019 N/A $10M N/A -737.4% COCP
FY2020 N/A $0M N/A -476.0% COCP
FY2022 $10M N/A -354.7% N/A SRZN
FY2024 $10M N/A -239.7% N/A SRZN
FY2025 $0M N/A -1210.6% N/A SRZN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
38d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 5th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
COCP UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact COCP Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
COCP Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $18.9M market capitalization and -3063.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs COCP Key Questions & Quantitative Answers

As of Nov 17, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Cocrystal Pharma, Inc. (COCP) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). SRZN carries a Unified Composite Score of 33.2/100 (SELL) at $29.98 (N/M Forward P/E, -485.4% operating margin), whereas COCP carries 38.7/100 (SELL) at $1.01 (N/M Forward P/E, -3063.6% operating margin). Composite vs. Pillar Nuance: While COCP currently prints a higher short-term Unified Composite Score (38.7/100 SELL vs. SRZN 33.2/100 SELL), SRZN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -3063.6% operating margin) and revenue trajectory (+408.6% vs. +26.9% YoY). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both SRZN (33.2/100 SELL) and COCP (38.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with COCP at +26.9% YoY revenue growth and +0.0% YoY earnings growth on $330,000 TTM revenue (N/A gross margin, -3063.6% operating margin). Across the 6-period historical trajectory (FY2011 to FY2025), SRZN cumulative revenue shifted +0.0% while COCP shifted +0.0%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for COCP.

COCP screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin), whereas COCP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 47.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus COCP (-311.7% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 67% Vol realized risk). By comparison, COCP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.